
5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update
Description
5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update
Summary
According to the recently published report '5-Hydroxytryptamine Receptor 7 - Drugs In Development, 2022'; 5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) pipeline Target constitutes close to 16 molecules. Out of which approximately 15 molecules are developed by companies and remaining by the universities/institutes.
5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) - 5-HT7 receptor is a member of the GPCR superfamily and it is activated by the serotonin (5-HT). The activity of this receptor is mediated by G proteins that stimulate adenylate cyclase. It plays an important role in autistic disorder and other neuropsychiatric disorders.
The report '5-Hydroxytryptamine Receptor 7 - Drugs In Development, 2022' outlays comprehensive information on the 5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.
It also reviews key players involved in 5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 3, 1, 5 and 3 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively.
Report covers products from therapy areas Central Nervous System, Cardiovascular, Gastrointestinal and Respiratory which include indications Bipolar Disorder (Manic Depression), Schizophrenia, Anxiety Disorders, Autism, Depression, Neuropathic Pain (Neuralgia), Psychiatric Disorders, Alzheimer's Disease, Attention Deficit Hyperactivity Disorder (ADHD), Cognitive Disorders, Crohn's Disease (Regional Enteritis), Dementia Associated With Alzheimer's Disease, Generalized Anxiety Disorder (GAD), Idiopathic Pulmonary Fibrosis, Inflammatory Pain, Major Depressive Disorder, Parkinson's Disease, Psychosis, Pulmonary Arterial Hypertension, Schizoaffective Disorder, Sleep Disorders and Ulcerative Colitis.
Note:Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
Summary
According to the recently published report '5-Hydroxytryptamine Receptor 7 - Drugs In Development, 2022'; 5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) pipeline Target constitutes close to 16 molecules. Out of which approximately 15 molecules are developed by companies and remaining by the universities/institutes.
5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) - 5-HT7 receptor is a member of the GPCR superfamily and it is activated by the serotonin (5-HT). The activity of this receptor is mediated by G proteins that stimulate adenylate cyclase. It plays an important role in autistic disorder and other neuropsychiatric disorders.
The report '5-Hydroxytryptamine Receptor 7 - Drugs In Development, 2022' outlays comprehensive information on the 5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.
It also reviews key players involved in 5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 3, 1, 5 and 3 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively.
Report covers products from therapy areas Central Nervous System, Cardiovascular, Gastrointestinal and Respiratory which include indications Bipolar Disorder (Manic Depression), Schizophrenia, Anxiety Disorders, Autism, Depression, Neuropathic Pain (Neuralgia), Psychiatric Disorders, Alzheimer's Disease, Attention Deficit Hyperactivity Disorder (ADHD), Cognitive Disorders, Crohn's Disease (Regional Enteritis), Dementia Associated With Alzheimer's Disease, Generalized Anxiety Disorder (GAD), Idiopathic Pulmonary Fibrosis, Inflammatory Pain, Major Depressive Disorder, Parkinson's Disease, Psychosis, Pulmonary Arterial Hypertension, Schizoaffective Disorder, Sleep Disorders and Ulcerative Colitis.
Note:Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape for 5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7)
- The report reviews 5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in 5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) targeted therapeutics and enlists all their major and minor projects
- The report assesses 5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to 5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for 5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding 5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
81 Pages
- Introduction
- Global Markets Direct Report Coverage
- 5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) – Overview
- 5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) – Therapeutics Development
- Products under Development by Stage of Development
- Products under Development by Therapy Area
- Products under Development by Indication
- Products under Development by Companies
- Products under Development by Universities/Institutes
- 5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) – Therapeutics Assessment
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- 5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) – Companies Involved in Therapeutics Development
- Adamed Pharma SA
- Avineuro Pharmaceuticals Inc
- Celon Pharma SA
- Core One Labs Inc
- Daya Drug Discoveries Inc
- H. Lundbeck AS
- Johnson & Johnson
- LB Pharmaceuticals Inc
- Praeventix LLC
- Reviva Pharmaceuticals Inc
- Sumitomo Pharma Co Ltd
- Sunovion Pharmaceuticals Inc
- 5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) – Drug Profiles
- 5HT7 Agonist – Drug Profile
- ADN-1184 – Drug Profile
- ADN-3662 – Drug Profile
- amisulpride – Drug Profile
- AVN-101 – Drug Profile
- brilaroxazine – Drug Profile
- DDD-028 – Drug Profile
- dimethyltryptamine – Drug Profile
- JNJ-18038683 – Drug Profile
- LB-102 – Drug Profile
- LB-102 LA – Drug Profile
- LB-104 – Drug Profile
- lurasidone hydrochloride – Drug Profile
- Small Molecules to Antagonize 5 HT7 Receptors for Crohn’s Disease and Ulcerative Colitis – Drug Profile
- Small Molecules to Target 5-HT7R for Sleep Disorders – Drug Profile
- vortioxetine hydrobromide – Drug Profile
- 5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) – Dormant Products
- 5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) – Discontinued Products
- 5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) – Product Development Milestones
- Featured News & Press Releases
- May 03, 2022: Reviva Pharmaceuticals announces update on RECOVER, a pivotal phase 3 global study evaluating brilaroxazine for the treatment of schizophrenia
- Apr 26, 2022: Reviva Pharmaceuticals to host key opinion leader webinar on brilaroxazine for schizophrenia and Other neuropsychiatric disorders
- Apr 11, 2022: Vortioxetine demonstrates advantage on daily and social functioning vs. desvenlafaxine in a large head-to-head study
- Mar 03, 2022: Core One Labs announces successful proof-of-concept for biosynthetic N-methyltryptamine (NMT)
- Feb 10, 2022: Core One Labs expects imminent breakthrough to produce NMT, Precursor to DMT
- Feb 09, 2022: Sunovion and Otsuka initiate Phase 3 clinical development of non-racemic amisulpride for the treatment of people with bipolar depression
- Feb 01, 2022: Reviva Pharmaceuticals announces first patients dosed in pivotal phase 3 study and long-term safety trial evaluating Brilaroxazine for the treatment of schizophrenia
- Jan 10, 2022: Reviva Pharmaceuticals Holdings receives FDA may proceed letter for pivotal phase 3 clinical trial and long-term safety trial evaluating Brilaroxazine for the treatment of Schizophrenia
- Dec 07, 2021: LB announces presentation of full results of dopamine receptor occupancy study of LB-102 at the 2021 ACNP conference
- Oct 04, 2021: LB Pharmaceuticals presents results of dopamine receptor occupancy studies of LB-102 at ECNP conference
- Oct 01, 2021: U.S. court issues decision in Trintellix patent litigation upholding active ingredient patent
- May 03, 2021: H. Lundbeck: New study finds that vortioxetine helps patients with MDD and comorbid Generalized Anxiety Disorder
- May 03, 2021: Sunovion presents data from marketed and late-stage development psychiatric compounds at the American Psychiatric Association (APA) Annual Meeting 2021
- Apr 26, 2021: Reviva announces full details of positive phase 2 clinical trial results for acute Schizophrenia
- Apr 22, 2021: Vortioxetine significantly improves overall functioning in a global real-world study in Major Depressive Disorder
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact Us
- Disclaimer
- List of Tables
- Table 1: Number of Products under Development by Stage of Development, 2022
- Table 2: Number of Products under Development by Therapy Areas, 2022
- Table 3: Number of Products under Development by Indications, 2022
- Table 4: Number of Products under Development by Companies, 2022
- Table 5: Products under Development by Companies, 2022
- Table 6: Products under Development by Companies, 2022 (Contd..1)
- Table 7: Products under Development by Companies, 2022 (Contd..2)
- Table 8: Number of Products under Investigation by Universities/Institutes, 2022
- Table 9: Products under Investigation by Universities/Institutes, 2022
- Table 10: Number of Products by Stage and Mechanism of Actions, 2022
- Table 11: Number of Products by Stage and Route of Administration, 2022
- Table 12: Number of Products by Stage and Molecule Type, 2022
- Table 13: Pipeline by Adamed Pharma SA, 2022
- Table 14: Pipeline by Avineuro Pharmaceuticals Inc, 2022
- Table 15: Pipeline by Celon Pharma SA, 2022
- Table 16: Pipeline by Core One Labs Inc, 2022
- Table 17: Pipeline by Daya Drug Discoveries Inc, 2022
- Table 18: Pipeline by H. Lundbeck AS, 2022
- Table 19: Pipeline by Johnson & Johnson, 2022
- Table 20: Pipeline by LB Pharmaceuticals Inc, 2022
- Table 21: Pipeline by Praeventix LLC, 2022
- Table 22: Pipeline by Reviva Pharmaceuticals Inc, 2022
- Table 23: Pipeline by Sumitomo Pharma Co Ltd, 2022
- Table 24: Pipeline by Sunovion Pharmaceuticals Inc, 2022
- Table 25: Dormant Products, 2022
- Table 26: Dormant Products, 2022 (Contd..1)
- Table 27: Discontinued Products, 2022
- List of Figures
- Figure 1: Number of Products under Development by Stage of Development, 2022
- Figure 2: Number of Products under Development by Therapy Areas, 2022
- Figure 3: Number of Products under Development by Top 10 Indications, 2022
- Figure 4: Number of Products by Mechanism of Actions, 2022
- Figure 5: Number of Products by Stage and Mechanism of Actions, 2022
- Figure 6: Number of Products by Routes of Administration, 2022
- Figure 7: Number of Products by Stage and Routes of Administration, 2022
- Figure 8: Number of Products by Stage and Molecule Type, 2022
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.